Month: November 2020
Excerpt from the Article: Parkinson’s disease (PD) is the second most common neurodegenerative disease, with patient numbers being expected to double worldwide in the next 20 years. The detailed molecular and cellular mechanisms underlying its pathogenesis remains unclear, although recent evidence has pointed towards the role of mitochondrial dysfunction in the onset of the disease.…
Read More
Excerpt from the Press Release: RADNOR, Pa. and GENEVA, Nov. 5, 2020 /PRNewswire/ — NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF,OTCBB:RLFTF) (“Relief”) announced that the independent Data Monitoring Committee (DMC) met yesterday and voted unanimously that NCT 04311697 should continue as planned to its full enrollment of 165 patients. Specifically, the committee identified no safety concerns…
Read More
Excerpt from the Press Release: BOSTON & LONDON–(BUSINESS WIRE)–Synthace Ltd and Ipsen, a global biopharmaceutical company focused on innovation and specialty care, have partnered to accelerate development of novel biotherapeutics targeting multiple therapeutic areas, including oncology, endocrinology, pain management, regenerative medicine and rare diseases. Ipsen has automated design and construction of therapeutic candidates using Synthace’s…
Read More
Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s BRILINTA® (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). The approval by the US…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has dosed the first patient in its Phase 1b trial evaluating SER-301 for the treatment of active mild-to-moderate ulcerative colitis (UC). SER-301 is an oral, rationally-designed microbiome therapeutic designed to dampen the aberrant gastrointestinal inflammation central to ulcerative colitis…
Read More
Excerpt from the Article: Pfizer Inc says its experimental COVID-19 vaccine is more than 90-percent effective, a major victory in the fight against a pandemic that has killed more than a million people, battered the world’s economy, and upended daily life. Pfizer and German partner BioNTech SE are the first drugmakers to release successful data…
Read More
Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Emulate, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Food and Drug Administration (FDA) to enable multiple studies across FDA offices in priority research areas, including programs to evaluate COVID-19 vaccines and understand human immune response against SARS-CoV-2, the…
Read More
Excerpt from the Article: LA JOLLA—As people across the world anxiously await the promise of an effective vaccine to end the coronavirus pandemic that has killed over 220,000 Americans and more than 1.1 million globally, it is important to remember a time when the world faced similar challenges and, through scientific research, found answers that…
Read More
For our Canadian clients! “Learn about the SR&ED Program and how it benefits health science companies. OBIO will have experts from the CRA to explain the eligibility criteria, what expenditures qualify, and how to file a scientific research and experimental development (SR&ED) claim for this year.” To Register Click the Button Below: Register Free!
Read More
Excerpt from the Press Release: OCEANSIDE, Calif., Oct. 29, 2020 /PRNewswire/ — Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today publication on the NIH clinical trials website1 of its newly initiated trial aiming to validate a blood-based diagnostic for predicting suicide risk. The Campbell Score™, which is a patent-pending method of quantifying inflammatory-associated biological markers,…
Read More- « Previous
- 1
- 2
- 3
- 4
- Next »